Eversept Partners, LP Chemo Centryx, Inc. Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2020 Nov 08, 2023	SELL	$38.58 - $65.07 $20.8 Million - $35.1 Million	-539,169 Reduced 92.96%	40,842 $2.35 Million
Q2 2020 Aug 13, 2020	SELL	$38.58 - $65.07 $20.8 Million - $35.1 Million	-539,169 Reduced 92.96%	40,842 $2.35 Million
Q1 2020 Nov 08, 2023	BUY	$32.73 - $50.78 $2.19 Million - $3.39 Million	66,822 Added 13.02%	580,011 $23.3 Million
Q1 2020 May 13, 2020	BUY	$32.73 - $50.78 $2.19 Million - $3.39 Million	66,822 Added 13.02%	580,011 $23.3 Million
Q4 2019 Nov 08, 2023	BUY	$6.81 - $39.55 $3.49 Million - $20.3 Million	513,189 New	513,189 $20.3 Million
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $3.49 Million - $20.3 Million	513,189 New	513,189 $20.3 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.